Description overdue on 24.08.2011

This drug is a stable eye drops based on recombinant Interferon . The staff of the research center under the leadership of Professor P.Ya.Gaponyuka Oftalmoferon created in 1999. These drops are protected by patent and have no analogues anywhere in the world. On the territory of the Russian Federation registered the drug in 2003, and in 2004 launched its production. Later, the drug registered in Kazakhstan, Belarus and Ukraine.

Pharmacological action:

This drug has a pronounced therapeutic effect in the treatment of viral diseases . Oftalmoferona have unique properties due to its complex composition. It has an antiviral effect, an anti-proliferative and anti-inflammatory action. Its constituent diphenhydramine   It provides anti, anti-allergic, anti-histamine effect, and is indispensable in acute viral infections of the cornea and conjunctiva. The antibacterial action has boric acid As a viral eye disease is often accompanied by a bacterial infection. The action of the drug prolongs the base resin drops, and she plays the role of "artificial tears", reducing or eliminating the need for extra instilljatsijah tears necessary in the case of viral infection for the treatment and prevention of disorders of the tear film. Oftalmoferon has a good range Antiviral Activity ; antibacterial, regenerative, immunomodulatory and anti-inflammatory effect.

Product:

This drug is released in a sterile vial ten ml. Additional dilution water is not required.

Composition:

Interferon human and diphenhydramine; polyethylene oxide, boric acid, Trilon B, sodium chloride, hypromellose, sodium acetate. In view of Oftalmoferon is a colorless and transparent liquid without foreign inclusions and sediment.

Indications:

The drug is used for herpes, bleeding, adenovirus conjunctivitis ; herpetic (kartoobraznom, tree, spot, vesicular) and adenovirus keratitis ; syndrome of "dry eye"; viral infections, conjunctivitis allergic origin.

Oftalmoferon prescribed as prophylaxis herpes infection   in the following and in the case of preoperative keratoplasty; lubrication of the corneal surface; after refractive surgery for decongestant action.

Dosage:

Patients who are in the acute stage, Oftalmoferon drip into the eyes a few drops 6-8 times per day. During extinction inflammation instillation amount should be reduced to two a day. Treatment should be up to the disappearance of any symptoms of the disease. In the treatment of dry eye should be applied two drops twice a day for six weeks. After keratoplasty using Oftalmoferon 2 weeks 3 times daily in parallel with anti-inflammatory and antibacterial therapy.

Storage conditions:

So, in a dry place, protected from the reach of children and the world scene should be stored Oftalmoferon. Shelf life of the drug is two years.

Side effects and contraindications:
This drug is not recommended to use individuals with individual intolerance or sensitivity to any components of the preparation.

Information about side effects Oftalmoferona not yet received.